A new effort by the pharmaceutical industry to improve access to prevention, care, and treatment of noncommunicable diseases in low- and middle-income countries is so far having mixed results.
Of 26 drug makers that agreed two years ago to participate in the Access Accelerated initiative, only 17 have registered one or more programs as part of the effort. On the other hand, a total of 73 programs were registered last year, up from 62 in 2017, although of those 73 programs, just 25 contained measurements for gauging progress and outcomes.
About the Author Reprints
